Brexit: IP one of the ‘least affected’ areas

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Brexit: IP one of the ‘least affected’ areas

AIPPI-2019-Brexit-panel-thumb

Speakers from the UKIPO and Novartis discussed Brexit at the AIPPI World Congress in London, as political protesters gathered outside the Supreme Court just round the corner

AIPPI-2019-Brexit-panel

The panel on Brexit yesterday could not have been more timely: as demonstrators gathered in front of the nearby UK Supreme Court to protest against the temporary suspension of Parliament, the speakers in the QEII Centre kicked off a discussion on how Brexit will affect IP.

Adam Williams, director of international policy at the UKIPO, began the session by telling audience members that his office has been working diligently to ensure a smooth transition for Brexit.

Williams went on to explain that Parliament has only granted his office permission to fix any gaps in legislation and not to tinker with policy changes.

The panellists said patents will be the area of IP least affected by Brexit because of pre-existing international harmonisation.

“Our real focus is trademarks and designs,” Williams said. “After leaving the EU, coverage of these rights will no longer extend to the UK. In the event of no-deal we are committed to giving owners rights similar to the EU rights they had before. Similar arrangements are being made as part of the withdrawal agreement.”

One area of concern for patent owners in the event of a no-deal Brexit is supplementary protection certificates (SPCs).

Williams said: “We recognise that while not many are issued, we know how valuable they are to pharmaceutical companies. In the event of a no-deal we will maintain a functioning SPC regime along the lines of the current system with the same rules and same timing periods and rights for those certificates.”

Ewan Nettleton, senior patent counsel for oncology at Novartis in Switzerland, said he was very pleased with all the provisions made by the UKIPO in preparation for Brexit. As SPCs are of particular importance to his industry, he emphasised that many of the same rights will be extended after Brexit.

“For us at Novartis, thanks to Adam’s diligent work, I am here to say we feel less uncomfortable. It appears that IP is one of the least affected areas by Brexit,” he said.

The Unified Patent Court (UPC) was discussed as a potential Brexit-related concern. With the UPC’s fate lingering in Germany’s Constitutional Court, audience members speculated on how the timing of the court’s decision might be affected by Brexit.

Responding to an audience member’s concern, Williams said any conversation about whether or not the UK – which has ratified the UPC Agreement – would be part of an operational UPC would depend on when Germany issues a decision. 

“In a perfect world you will like us to have the discussion while we are in the EU; logically that is a more pleasant environment. If we exit in October … the conversation is in a more different atmosphere. We are sure of the benefits of the UK to be part of the UPC. My experience says if there is a political will you will find a legal solution.”

Nettleton added that from an industry perspective the UPC would be much stronger with UK involvement.

“It was a surprise to me that I heard the UK would still want to participate in the UPC after Brexit. But then again, after Brexit, nothing can surprise you,” he said.

The Congress finishes today.

Image credit: Simon Callaghan Photography

more from across site and SHARED ros bottom lb

More from across our site

McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks
IP firms may be growing more comfortable with external capital, but uncertainty over who could ultimately own the business is complicating the investment pitch
The former Western District of Texas judge addresses perceptions of his courtroom, reveals what comes next as he returns to practice at A&O Shearman and explains why marathon running is ‘cathartic’
International Anti-Counterfeiting Coalition says it has been blocked from hosting its annual event in the city, ending a long tradition of holding the gathering in the days leading up to INTA’s flagship event
The ITC is a powerful tool for litigators, practitioners say, as the threat of an exclusion order on a critical tech component could mean disrupting the entire data centre's operations
Anna Toh plans to expand Rajah & Tann’s soft IP capabilities, leveraging its Southeast Asia network to support clients on cross-border portfolio management and commercial strategy
The Canadian boutique’s new IP lead says he wants to build a tech-enabled IP practice aimed at giving startups senior expertise away from the traditional ‘big law’ set-up
Qantm IP’s acquisition of Henry Goh & Co shows shifting attitudes towards private equity, with firms increasingly viewing external backing as a normal route to expansion rather than a source of concern
The firm’s involvement in prominent AI cases drew litigator Christian Mammen to join from Womble Bond Dickinson, as US firms continue to bolster AI-focused practices
Two judicial appointments confirmed in Paris and Mannheim, while cross-border injunctions and high-profile procedural rulings keep major patent practices occupied
Gift this article